{"commentary":{"count":9,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":5,"x_thread":3,"podcast":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06345079\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"STOPNET","nct_id":"NCT06345079","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=stopnet-nct06345079. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"STOPNET","arms":[{"description":"Patients randomised to continue SSA will receive a SSA injection ≥28 days prior to the first PRRT cycle, during PRRT cycle, and every 4 weeks after completion of PRRT.","label":"Continue SSA","type":"ACTIVE_COMPARATOR"},{"description":"Patients randomised to cease SSA will receive SSA injection ≥28 days prior to their first cycle of PRRT. Patients will not receive any further long acting SSA injections after this time.","label":"Cease SSA","type":"EXPERIMENTAL"}],"collaborators":["Canadian Cancer Trials Group"],"completion_date":{"date":"2028-06","type":"ESTIMATED"},"conditions":["Neuroendocrine Tumors"],"enrollment":{"count":78,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Cessation of somatostatin analogues","type":"DRUG"},{"name":"Continuation of somatostatin analogues","type":"DRUG"}],"last_update":"2026-09-10","lead_sponsor":"Australasian Gastro-Intestinal Trials Group","official_title":"A Randomised Study of Cessation of Somatostatin Analogues After Peptide Receptor Radionuclide Therapy in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours (STOPNET)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-09","type":"ESTIMATED"},"primary_outcomes":[{"measure":"20-month progression free survival rate after PRRT","timeFrame":"20 months"},{"measure":"Assess the barriers which would impede the feasibility of a subsequent phase 3 trial","timeFrame":"20 months"}],"references":[],"start_date":{"date":"2024-10-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours","url":"https://clinicaltrials.gov/study/NCT06345079"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/stopnet-nct06345079"}